Axa Raises Holdings in Agios Pharmaceuticals Inc (AGIO)

Axa raised its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 17.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 203,984 shares of the biopharmaceutical company’s stock after buying an additional 30,368 shares during the quarter. Axa owned approximately 0.35% of Agios Pharmaceuticals worth $15,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. FMR LLC lifted its stake in Agios Pharmaceuticals by 0.5% in the second quarter. FMR LLC now owns 8,640,843 shares of the biopharmaceutical company’s stock valued at $727,818,000 after buying an additional 41,832 shares during the last quarter. BlackRock Inc. lifted its stake in Agios Pharmaceuticals by 1.3% in the second quarter. BlackRock Inc. now owns 3,248,251 shares of the biopharmaceutical company’s stock valued at $273,601,000 after buying an additional 42,198 shares during the last quarter. First Trust Advisors LP lifted its stake in Agios Pharmaceuticals by 58.8% in the third quarter. First Trust Advisors LP now owns 1,162,010 shares of the biopharmaceutical company’s stock valued at $89,614,000 after buying an additional 430,216 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Agios Pharmaceuticals by 459.8% in the second quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock valued at $34,315,000 after buying an additional 334,617 shares during the last quarter. Finally, Woodford Investment Management Ltd purchased a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $32,849,000. Institutional investors own 94.93% of the company’s stock.

A number of equities research analysts have weighed in on AGIO shares. BidaskClub cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, October 6th. Cowen reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, November 2nd. Oppenheimer reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Thursday, November 1st. Cann reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Friday, November 16th. Finally, Leerink Swann assumed coverage on Agios Pharmaceuticals in a research note on Monday, September 24th. They set a “market perform” rating and a $80.00 price target for the company. Six research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $96.27.

Agios Pharmaceuticals stock opened at $64.24 on Friday. Agios Pharmaceuticals Inc has a 12 month low of $51.62 and a 12 month high of $99.82. The company has a market cap of $3.62 billion, a PE ratio of -9.52 and a beta of 2.04.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.62) by ($0.01). Agios Pharmaceuticals had a negative return on equity of 48.51% and a negative net margin of 461.78%. The company had revenue of $15.20 million for the quarter, compared to analysts’ expectations of $22.72 million. During the same quarter last year, the company earned ($1.59) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 33.8% compared to the same quarter last year. As a group, research analysts forecast that Agios Pharmaceuticals Inc will post -6.12 EPS for the current fiscal year.

In other news, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $83.07, for a total transaction of $249,210.00. Following the completion of the sale, the insider now owns 60,196 shares in the company, valued at $5,000,481.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher Bowden sold 1,700 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $80.03, for a total value of $136,051.00. Following the sale, the insider now owns 1,224 shares of the company’s stock, valued at approximately $97,956.72. The disclosure for this sale can be found here. Insiders have sold 24,255 shares of company stock valued at $1,789,827 in the last 90 days. Company insiders own 3.02% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by WKRB News and is the property of of WKRB News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.wkrb13.com/2018/11/25/axa-raises-holdings-in-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Read More: What factors cause inflation to rise?

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply